US health officials say Ebola treatment trial to start soon in Liberia

Jan 22 (Reuters) - U.S. health officials said on Thursday that they are planning to conduct larger phase 2/3 clinical trials starting in the next two weeks in Liberia to determine if an Ebola treatment being developed by GlaxoSmithKline and another by Newlink Genetics with Merck & Co are safe and effective.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.